The endocannabinoid system plays contrasting roles in liver disease: CB1 receptor activation promotes fibrosis, steatosis, and cancer progression, while CB2 activation inhibits fibrosis, suggesting targeted cannabinoid therapy could benefit liver patients.
Hepatologists, liver disease patients, and researchers studying cannabinoid receptor pharmacology.
CB1 promotes liver fibrosis while CB2 inhibits it
What the researchers found
CB1 receptor stimulation increases fibrosis and inflammatory activity by stimulating stellate cells and may promote liver steatosis and carcinogenesis. CB2 receptor activation inhibits fibrosis. In end-stage liver disease, the endocannabinoid system contributes to encephalopathy, portal hypertension, splanchnic vasodilatation, and cirrhotic cardiomyopathy.
Why it matters
Understanding the opposing roles of CB1 and CB2 receptors in liver disease opens the door to targeted cannabinoid therapies that could inhibit fibrosis (via CB2) without promoting it (via CB1). This has implications for the millions of people with chronic liver disease worldwide.
The numbers in context
CB1 and CB2 receptors expressed in myofibroblasts and liver endothelial cells; expression elevated in chronic liver disease
How the study worked
Review of the endocannabinoid system's role in chronic liver diseases, examining CB1 and CB2 receptor expression and function in liver cells.
What this study cannot tell us
Review article without new clinical data. The translation from receptor-level understanding to clinical treatments faces many hurdles. Most evidence is preclinical.
How to read the evidence
Review of preclinical and clinical literature. Conceptually important but no new data presented.
When this study was published
Published in 2024.
The bigger picture
The endocannabinoid system's dual role in liver disease represents both a risk (CB1-mediated fibrosis) and opportunity (CB2-mediated protection). Selective CB2 agonists could potentially become a new class of liver-protective drugs.
Questions still open
- Could selective CB2 agonists become treatments for liver fibrosis?
- Should cannabis users with chronic liver disease be concerned about CB1-mediated effects?
Common questions
Is cannabis bad for the liver?
Could cannabinoids treat liver disease?
Read the original research
Cannabinoids and the endocannabinoid system in liver diseases.
Clinical and experimental hepatology, 10(4), 211-217
Citation
Parfieniuk-Kowerda, Anna; Martonik, Diana; Andrzejuk, Aleksandra; Tarasik, Aleksander; Flisiak, Robert. (2024). Cannabinoids and the endocannabinoid system in liver diseases.. Clinical and experimental hepatology, 10(4), 211-217. https://doi.org/10.5114/ceh.2024.145358
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk